[IS-FR-129] Macula Society and the National Eye Institute/National Institutes of Health Session: Advances in Therapies for Diabetic Retinopathy
- Apr 04 (Fri)
- 08:30 - 10:00
- Room 23 - Imperial Hotel 3F Fuji
- Retina - Medical
- Chair）Anat Loewenstein
- The prevalence of diabetes, estimated by the World Health Organization to be 346 million currently, is projected to increase rapidly throughout the world. The risk of visual loss is markedly increased in person with diabetes. With a substantial increase in the risk of developing diabetes, the discovery of effective therapies of diabetic retinopathy, especially with preventive measures, is crucial. Purpose/Relevance: This addresses a great public health issue. The purpose of the presentation is to provide information on the latest therapies available for the various stages of diabetic retinopathy. Current Outcomes: The audience may be familiar with some of the results of previous studies but the more recent studies provide very important information for new therapies that can potentially improve the visual acuity of persons with diabetic retinopathy and improve the vision associated quality of life. Results: The attendee will gain a better understanding of the disease process but more important, also have exposure to the most recent research results regarding the vision saving therapies for diabetic retinopathy.